1 |
J. Bernstein, Polymorphism and the investigation of structure-property relations in organic solids, Int. Union Crystallogr. Crystallogr. Symp., 4 (Org. Cryst. Chem.), 6-26 (1991).
|
2 |
F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Theor. Chem., 69 (Struct. Prop. Mol. Cryst.), 211-234 (1990).
|
3 |
N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa,Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-41 (1989).
|
4 |
E. F. Fiese and T.A. Hagen, Preformulation : In Theory and Practice of Industrial Pharmacy, L. Lachman, H. A. Lieberman and J. L. Kanig (Ed.), Third Edition, Lea and Febiger, Philadelphia, pp 176-181 (1986)
|
5 |
H. G. Brittain and D. J. W. Grant, Effects of polymorphism and solid-state solvation on solubility and dissolution rate : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 279-330 (1999)
|
6 |
Y. T. Sohn, Crystal forms of an angiotensin II receptor antagonist BR-A657, J. Therm. Anal. Cal., 89(3), 799-802 (2007).
DOI
ScienceOn
|
7 |
Y. T. Sohn, Effect of crystal form on bioavailability, J. Kor. Pharm. Sci., 34, 443-452 (2004).
과학기술학회마을
|
8 |
W. C. Kind, P. Varlashkin and C. Li, The applicability of powder x-ray diffraction to the quantification of drug substance polymorphs using a model organic system, Powder Diffr., 8, 180-187 (1993).
DOI
|
9 |
M. R. Caira, M. Zanol, T. Peveri, A. Gazzaniga and F. Giordano, Structural characterization of two polymorphic forms of piroxicam pivalate, J. Pharm. Sci., 87, 1608-1614 (1998).
DOI
ScienceOn
|
10 |
A. Burger and K. T. Koller, Polymorphism and pseudopolymorphism on nifedifine, Sci. Pharm., 64, (1996).
|
11 |
A. David, E. Balogh, G. Csoka and I. Racz, Methodological aspects of examination of the polymorphism of vincristine sulfate, Sci. Pharm., 64, 311-318 (1996).
|
12 |
E. A. Lee and Y. T. Sohn, Crystal forms of a capsaicin derivative analgesic DA-5018, J. Therm. Anal. Cal., 93(3), 871-874 (2008).
DOI
ScienceOn
|
13 |
Y. T. Sohn and B. Y. Park, Characterization of the physicochemical properties of KR-31378, Arch. Pharm. Res., 26, 526-531 (2003).
DOI
ScienceOn
|
14 |
Y. T. Sohn and H. O. Seo, Crystal Forms of Ketorolac, Arch. Pharm. Res., 27, 357-360 (2004).
DOI
ScienceOn
|
15 |
A. Bauer-Brandl and Y. T. Sohn, Crystal modifications of cimetidine: Characterization and evaluation for manufacturing of dosage forms, Eur. J. Pharm. Biopharm., 40 (Suppl.), (1994).
|
16 |
Y. T. Sohn, J. K. Lee and W. B. Im, Polymorphism of clarithromycin, Arch. Pharm. Res., 23, 381-384 (2000).
DOI
ScienceOn
|
17 |
Y. T. Sohn and S. Y. Kim, Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids, Arch.Pharm. Res., 25, 556-559 (2002).
DOI
ScienceOn
|
18 |
Y. T. Sohn and S. H. Park, Crystal Forms of Cephradine, Arch. Pharm. Res., 29, 178-182 (2006).
DOI
ScienceOn
|
19 |
Y. T. Sohn, Effect of polymorphism on bioavailability of amoxycillin, Yakhak Hoeji., 39, 438-443 (1995).
|
20 |
A. Burger, Zur Interpretation von Polymorphie-untersuchungen, Acta Pharm. Technol., 28, 1-20 (1982).
|
21 |
J. Haleblian and W. McCrone, Pharmaceutical applications of polymorphism, J. Pharm. Sci., 58, (1969).
DOI
|
22 |
H. G. Brittain, Methods for the characterization of polymorphs and sovates : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 227-278 (1999)
|
23 |
B. D. Sharma, Allotropes and polymorphs, J. Chem. Educ., 64, 404-407 (1987).
DOI
|
24 |
J. Bernstein, Conformational polymorphism, Stud. Org. Chem. (Amsterdam), 32(Org. Solid Statd Chem.), 471-518 (1987).
|
25 |
M. Kitamura, Polymorphism in crystallization, Kagaku kogaku, 55, 263-264 (1991).
|
26 |
Y. T. Sohn and Y. H. Lee., Polymorphism of Doxazocin mesylate, Arch. Pharm. Res., 28, 732-737 (2005).
DOI
ScienceOn
|
27 |
Y. T. Sohn and S. H. Kim, Polymorphism and pseudopolymorphism of acyclovir, Arch. Pharm. Res., 31, 231-234 (2008).
DOI
ScienceOn
|